Results 31 to 40 of about 6,202 (185)
Evidence that GPVI is Expressed as a Mixture of Monomers and Dimers, and that the D2 Domain is not Essential for GPVI Activation [PDF]
Collagen has been proposed to bind to a unique epitope in dimeric glycoprotein VI (GPVI) and the number of GPVI dimers has been reported to increase upon platelet activation.
Joanne C. Clark +14 more
openalex +2 more sources
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with high morbidity and mortality. Excessive neutrophil infiltration into the pulmonary airspace is the main cause for the acute inflammation and lung injury. Platelets
Philipp Burkard +11 more
semanticscholar +1 more source
Rac Inhibition Causes Impaired GPVI Signalling in Human Platelets through GPVI Shedding and Reduction in PLCγ2 Phosphorylation [PDF]
Rac1 is a small Rho GTPase that is activated in platelets upon stimulation with various ligands, including collagen and thrombin, which are ligands for the glycoprotein VI (GPVI) receptor and the protease-activated receptors, respectively. Rac1-deficient
Raluca A. I. Neagoe +5 more
openalex +2 more sources
Colchicine has been demonstrated to reduce cardiovascular death, myocardial infarction (MI), ischemic stroke, and ischemia-driven coronary revascularization in people with coronary artery disease (CAD).
G. Pennings +4 more
semanticscholar +1 more source
Receptor homodimerisation significantly prolongs the lifetime of ligand-induced crosslinking of CLEC-2 but not GPVI [PDF]
Clark J +5 more
europepmc +2 more sources
Fragmented thrombi, targeted solutions: Exploring GPVI inhibition in high-shear environments. [PDF]
Rabinowitz EJ, Bark D.
europepmc +3 more sources
Antisense oligonucleotide (ASO) is a therapeutic modality that enables selective modulation of undruggable protein targets. However, dose- and sequence-dependent platelet count reductions have been reported in nonclinical studies and clinical trials. The
Allan Valenzuela +6 more
semanticscholar +1 more source
Absence of bleeding upon dual antiplatelet therapy in a patient with a immune GPVI deficiency
Acquired deficiencies in platelet glycoprotein VI are rare and have not been found associated with other defects. Here we report the case of a 64-year old male patient presenting an immune GPVI deficiency associated to a mutation in the alpha-actinin ...
Stéphane Loyau Inserm +5 more
doaj +1 more source
Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial
Background Glenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunction,
Julien Pottecher +14 more
openalex +3 more sources
The association between endometriosis and autoimmune diseases is well known, however no acquired platelet function defect has been described so far. We describe the case of two patients with endometriosis associated with an antiplatelet glycoprotein VI ...
Stéphane Loyau +12 more
doaj +1 more source

